보고서 요약(국문)

개요
전 세계 그레이브스 안병증 치료 시장은 2022년 XX백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 XX%의 성장률을 보이며 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
그레이브스 안병증은 안와 및 안와 주변 조직의 자가면역 염증성 질환으로, 상안검 후퇴, 눈꺼풀 처짐, 부기, 충혈, 결막염, 안구 돌출 등의 증상을 특징으로 합니다. 자가항체가 눈 근육의 섬유아세포를 공격하여 이 섬유아세포가 지방세포로 분화됩니다. 지방세포와 근육이 비대해지고 염증이 발생합니다.
이 질환은 갑상선 호르몬 수치 조절을 통해 치료할 수 있습니다. 코르티코스테로이드는 안와 염증 감소에 효과적입니다. 테프로투무맙이라는 약물도 이 질환 치료에 사용됩니다.

시장 동향: 성장 동인 및 제약 요인
질병 유병률 증가
질병 유병률 증가는 다양한 의약품에 대한 수요를 증가시키고 있으며, 질병에 대한 인식 제고는 치료를 받는 사람들의 수를 늘리고 있습니다.
유병률 증가는 개인의 면역 체계에 맞춰 알레르기나 부작용 없이 치료할 수 있는 정밀 의학에 대한 수요를 증가시키고 있습니다. 이 질환은 남성보다 여성에게 더 흔합니다. 예를 들어, 2023년 네이처(Nature)지에 따르면 그레이브스 안병증 발병률은 여성에서 남성보다 2.4배 더 높은 것으로 추정됩니다. 따라서 위의 요인들이 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다.
제약 요인
약물 관련 부작용
특히 코르티코스테로이드와 같은 항염증제를 장기간 복용할 경우 골다공증, 피부 얇아짐과 같은 심각한 부작용이 발생할 수 있습니다. 정맥 주사(IV) 투여 시에는 메스꺼움, 설사, 근육 경련, 혈당 상승과 같은 부작용이 나타날 수 있습니다.

시장 세분화 분석
전 세계 그레이브스 안병증 치료 시장은 약물, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
코르티코스테로이드 부문은 시장 점유율의 38.6%를 차지했습니다.
코르티코스테로이드는 그레이브스 안병증 치료의 1차 치료제로 간주됩니다. 그레이브스 안병증은 코르티코스테로이드 사용으로 예방할 수 있는 복잡한 자가면역 질환입니다. 코르티코스테로이드 약물의 효능은 이 부문을 시장의 주도적인 위치로 유지할 것으로 예상됩니다.
그레이브스 안병증에 대한 코르티코스테로이드 펄스 요법은 그레이브스 갑상선기능항진증의 재발률을 감소시킵니다. 글루코코르티코이드 요법은 특히 활동성 중등도-중증 환자에게 주요 치료법이며, 근거 기반 지원이 필요합니다.
활동성 중등도-중증 그레이브스 안병증(GO) 치료는 고용량 정맥 글루코코르티코이드(GCiv) 투여를 기반으로 합니다. 코르티코스테로이드는 단독으로 또는 안와 방사선 치료와 병용하여 중증 그레이브스 안병증 치료에 널리 사용됩니다. 따라서 위의 요인들이 해당 부문의 시장 점유율을 주도하는 요인으로 작용하고 있습니다.
지역 분석
북미는 전 세계 그레이브스 안병증 치료 시장에서 상당한 비중을 차지할 것으로 예상됩니다.
북미 지역은 가장 큰 시장 점유율을 기록했습니다. 질병 유병률 증가, 치료제 개발 연구, 그리고 이 지역의 제약 생산 증가는 북미 지역 시장 성장을 견인할 것으로 예상됩니다.
예를 들어, 미국 희귀질환기구(NORD)의 2022년 보고서에 따르면, 그레이브스 안병증 발병률은 일반 여성 인구 10만 명당 16명, 남성 인구 10만 명당 2.9명으로 추정됩니다. 따라서 질병 유병률 증가는 북미 지역 시장 성장을 촉진할 것으로 예상됩니다.

COVID-19 영향 분석
COVID-19는 그레이브스병 안병증 시장에 중간 정도의 영향을 미쳤습니다. 공급망 차질, 의약품 승인 감소, 제약 회사들의 COVID-19 치료제 생산으로의 전환 등이 시장에 부정적인 영향을 미쳤습니다.

시장 세분화
약물별
• 코르티코스테로이드
o 프레드니솔론
o 디하이드로코르티손
o 글루코코르티코이드
• 인슐린 유사 성장인자-1
o 테프로투무맙
• 티오나미드
• 방사성 요오드
투여 경로별
• 경구
• 주사
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
상당한 시장 점유율을 차지하는 주요 기업으로는 Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutics 등이 있습니다. Regeneron Pharmaceuticals, HanAll Biopharma, ValenzaBio, Bausch & Lomb 등이 주요 기업입니다.

보고서 구매 이유:

• 약물, 투여 경로, 유통 채널 및 지역별 그레이브스 안병증 치료 시장의 글로벌 세분화를 시각화하고 주요 상업 자산 및 기업을 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 식별합니다.

• 모든 세그먼트를 포함한 그레이브스 안병증 치료 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석을 담은 PDF 보고서를 제공합니다.

• 주요 기업의 핵심 제품을 포함한 제품 맵핑을 Excel 파일로 제공합니다.

글로벌 그레이브스 안병증 치료 시장 보고서는 약 55개의 표, 56개의 그림, 179페이지로 구성됩니다.
주요 고객 (2023년 기준):
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 연구 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Graves Ophthalmopathy Treatment Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.
Graves ophthalmopathy is an autoimmune inflammatory disorder of the orbit and periorbital tissues that is characterized by upper eyelid retraction, lid lag, swelling, redness, conjunctivitis, and bulging eyes. The autoantibodies target the fibroblasts in the eye muscles, and those fibroblasts will differentiate into fat cells. Fat cells and muscles expand and become inflamed.
The disease can be treated by regulating the thyroid hormone levels. Corticosteroids are efficient in reducing orbital inflammation. The medication teprotumumab is also used to treat the condition.
Market Dynamics: Drivers & Restraints
Increasing prevalence of the disease
The increasing prevalence of the disease increases the demand for a variety of medications available and the increasing awareness among individuals about the disease increases the number of individuals undergoing treatment.
The increased prevalence is increasing the demand for precision medicine which suits the individual’s immune system without causing allergies or side effects to the individual. The disease is more common in women when compared to men. For instance, according to the Nature Journal in 2023, it is estimated that Graves ophthalmopathy incidence is 2.4 times more common in women than in men. Thus, the above factors are expected to drive market growth during the forecast period.
Restraint
Side effects associated with the medication
The side effects associated with the long-term intake of anti-inflammatory drugs specifically corticosteroids are associated with serious adverse effects such as osteoporosis, and thinning of the skin. The IV medication can cause side effects such as nausea, diarrhea, muscle spasms, and elevated blood sugar levels.
Segment Analysis
The global graves ophthalmopathy treatment market is segmented based on medication, route of administration, distribution channel, and region.
Corticosteroids segment accounted for 38.6% of the market share
Corticosteroids are considered the first-line therapy for the treatment of Graves' ophthalmopathy. It is a complicated autoimmune disease that can be prevented with the usage of corticosteroids. The efficiency of the corticosteroid medication against the disease is expected to hold the segment in the dominant position.
Corticosteroid Pulse Therapy for Graves' Ophthalmopathy reduces the relapse rate of Graves' hyperthyroidism. Glucocorticoid therapy is the mainstay of treatment especially for active moderate to severe patients, which needs evidence-based support.
The treatment of active moderate-severe Graves' ophthalmopathy (GO) is based on the administration of high-dose intravenous glucocorticoids (GCiv). Corticosteroids, alone or in combination with radiotherapy of the orbit, are widely used to treat severe Graves' ophthalmopathy. Thus, the above factors are holding the segment in the dominant position in the market share.
Geographical Analysis
North America is expected to hold a significant position in the global Graves ophthalmopathy treatment market share
North American region accounted for the largest market share. The increasing prevalence of the disease, the research carried out in introducing the medications, and the increased pharmaceutical production in the region is expected to drive the market growth in the region.
For instance, according to a report by the National Organization for Rare Disorders, Inc. (NORD) in 2022, it is estimated that the Graves ophthalmopathy occurrence is 16 per 100,000 women in the general population and 2.9 per 100,000 men in the general population. Thus, the increasing prevalence of the disease is expected to drive the market growth in the region.
COVID-19 Impact Analysis
The COVID-19 has impacted the Graves ophthalmopathy market moderately. The obstruction in the supply chain, the reduced approvals of the drugs, and the shift of the pharmaceutical companies towards the manufacturing of COVID-19 medicine has impacted the market negatively.
Market Segmentation
By Medication
• Corticosteroids
o Prednisolone
o Dehydrocortisone
o Glucocorticoids
• Insulin-like growth factor-1
o Teprotumumab
• Thionamides
• Radioiodine
By Route of Administration
• Oral
• Parenteral
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The leading companies with a significant market share include Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutics, Regeneron Pharmaceuticals, HanAll Biopharma, ValenzaBio, and Bausch & Lomb among others.
Why Purchase the Report?
• To visualize the global graves ophthalmopathy treatment market segmentation based on medication, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of graves ophthalmopathy treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global Graves ophthalmopathy treatment market report would provide approximately 55 tables, 56 figures, and 179 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Medication
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing prevalence of the disease
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Side effects associated with the medication
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Medication
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
7.1.2. Market Attractiveness Index, By Medication
7.2. Corticosteroids*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.2.1. Prednisolone
7.2.2.2. Dehydrocortisone
7.2.2.3. Glucocorticoids
7.3. Insulin-like growth factor-1
7.3.1. Teprotumumab
7.4. Thionamides
7.5. Radioiodine
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Parenteral
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Immunovant Sciences*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Novartis
12.3. Viridian Therapeutics
12.4. Sling Therapeutics
12.5. Regeneron Pharmaceuticals
12.6. HanAll Biopharma
12.7. ValenzaBio
12.8. Bausch & Lomb
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Immunovant Sciences, 4.	Key Developments, Novartis, Viridian Therapeutics, Sling Therapeutics, Regeneron Pharmaceuticals, HanAll Biopharma, ValenzaBio, Bausch & Lomb

표 목록 (Tables)

List of Tables

Table 1 Global Graves Ophthalmopathy Treatment Market Value, By Medication, 2025, 2029 & 2033 (US$ Billion)

Table 2 Global Graves Ophthalmopathy Treatment Market Value, By Disease Severity, 2025, 2029 & 2033 (US$ Billion)

Table 3 Global Graves Ophthalmopathy Treatment Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)

Table 4 Global Graves Ophthalmopathy Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 5 Global Graves Ophthalmopathy Treatment Market Value, By Medication, 2025, 2029 & 2033 (US$ Billion)

Table 6 Global Graves Ophthalmopathy Treatment Market Value, By Medication, 2022-2033 (US$ Billion)

Table 7 Global Graves Ophthalmopathy Treatment Market Value, By Disease Severity, 2025, 2029 & 2033 (US$ Billion)

Table 8 Global Graves Ophthalmopathy Treatment Market Value, By Disease Severity, 2022-2033 (US$ Billion)

Table 9 Global Graves Ophthalmopathy Treatment Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)

Table 10 Global Graves Ophthalmopathy Treatment Market Value, By End-User, 2022-2033 (US$ Billion)

Table 11 Global Graves Ophthalmopathy Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 12 Global Graves Ophthalmopathy Treatment Market Value, By Region, 2022-2033 (US$ Billion)

Table 13 North America Graves Ophthalmopathy Treatment Market Value, By Medication, 2022-2033 (US$ Billion)

Table 14 North America Graves Ophthalmopathy Treatment Market Value, By Disease Severity, 2022-2033 (US$ Billion)

Table 15 North America Graves Ophthalmopathy Treatment Market Value, By End-User, 2022-2033 (US$ Billion)

Table 16 North America Graves Ophthalmopathy Treatment Market Value, By Country, 2022-2033 (US$ Billion)

Table 17 Europe Graves Ophthalmopathy Treatment Market Value, By Medication, 2022-2033 (US$ Billion)

Table 18 Europe Graves Ophthalmopathy Treatment Market Value, By Disease Severity, 2022-2033 (US$ Billion)

Table 19 Europe Graves Ophthalmopathy Treatment Market Value, By End-User, 2022-2033 (US$ Billion)

Table 20 Europe Graves Ophthalmopathy Treatment Market Value, By Country, 2022-2033 (US$ Billion)

Table 21 Asia-Pacific Graves Ophthalmopathy Treatment Market Value, By Medication, 2022-2033 (US$ Billion)

Table 22 Asia-Pacific Graves Ophthalmopathy Treatment Market Value, By Disease Severity, 2022-2033 (US$ Billion)

Table 23 Asia-Pacific Graves Ophthalmopathy Treatment Market Value, By End-User, 2022-2033 (US$ Billion)

Table 24 Asia-Pacific Graves Ophthalmopathy Treatment Market Value, By Country, 2022-2033 (US$ Billion)

Table 25 South America Graves Ophthalmopathy Treatment Market Value, By Medication, 2022-2033 (US$ Billion)

Table 26 South America Graves Ophthalmopathy Treatment Market Value, By Disease Severity, 2022-2033 (US$ Billion)

Table 27 South America Graves Ophthalmopathy Treatment Market Value, By End-User, 2022-2033 (US$ Billion)

Table 28 South America Graves Ophthalmopathy Treatment Market Value, By Country, 2022-2033 (US$ Billion)

Table 29 Middle East and Africa Graves Ophthalmopathy Treatment Market Value, By Medication, 2022-2033 (US$ Billion)

Table 30 Middle East and Africa Graves Ophthalmopathy Treatment Market Value, By Disease Severity, 2022-2033 (US$ Billion)

Table 31 Middle East and Africa Graves Ophthalmopathy Treatment Market Value, By End-User, 2022-2033 (US$ Billion)

Table 32 Middle East and Africa Graves Ophthalmopathy Treatment Market Value, By Country, 2022-2033 (US$ Billion)

Table 33 Amgen Inc.: Overview

Table 34 Amgen Inc.: Product Portfolio

Table 35 Amgen Inc.: Key Developments

Table 36 Immunovant, Inc.: Overview

Table 37 Immunovant, Inc.: Product Portfolio

Table 38 Immunovant, Inc.: Key Developments

Table 39 Viridian Therapeutics, Inc.: Overview

Table 40 Viridian Therapeutics, Inc.: Product Portfolio

Table 41 Viridian Therapeutics, Inc.: Key Developments

Table 42 argenx: Overview

Table 43 argenx: Product Portfolio

Table 44 argenx: Key Developments

Table 45 Tourmaline Bio, Inc.: Overview

Table 46 Tourmaline Bio, Inc.: Product Portfolio

Table 47 Tourmaline Bio, Inc.: Key Developments

Table 48 F. Hoffmann-La Roche Ltd: Overview

Table 49 F. Hoffmann-La Roche Ltd: Product Portfolio

Table 50 F. Hoffmann-La Roche Ltd: Key Developments

Table 51 Sling Therapeutics: Overview

Table 52 Sling Therapeutics: Product Portfolio

Table 53 Sling Therapeutics: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US$ Billion)

Figure 2 Global Graves Ophthalmopathy Treatment Market Share, By Medication, 2024 & 2033 (%)

Figure 3 Global Graves Ophthalmopathy Treatment Market Share, By Disease Severity, 2024 & 2033 (%)

Figure 4 Global Graves Ophthalmopathy Treatment Market Share, By End-User, 2024 & 2033 (%)

Figure 5 Global Graves Ophthalmopathy Treatment Market Share, By Region, 2024 & 2033 (%)

Figure 6 Global Graves Ophthalmopathy Treatment Market Y-o-Y Growth, By Medication, 2023-2033 (%)

Figure 7 Monoclonal Antibodies Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US$ Billion)

Figure 8 Corticosteroids Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US$ Billion)

Figure 9 Antithyroid Medications Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US$ Billion)

Figure 10 Others Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US$ Billion)

Figure 11 Global Graves Ophthalmopathy Treatment Market Y-o-Y Growth, By Disease Severity, 2023-2033 (%)

Figure 12 Mild Disease Severity in Global Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US$ Billion)

Figure 13 Moderate Disease Severity in Global Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US$ Billion)

Figure 14 Severe Disease Severity in Global Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US$ Billion)

Figure 15 Global Graves Ophthalmopathy Treatment Market Y-o-Y Growth, By End-User, 2023-2033 (%)

Figure 16 Hospitals End-User in Global Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US$ Billion)

Figure 17 Specialty Clinics End-User in Global Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US$ Billion)

Figure 18 Academic and Research Institutes End-User in Global Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US$ Billion)

Figure 19 Others End-User in Global Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US$ Billion)

Figure 20 Global Graves Ophthalmopathy Treatment Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 21 North America Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US$ Billion)

Figure 22 North America Graves Ophthalmopathy Treatment Market Share, By Medication, 2024 & 2033 (%)

Figure 23 North America Graves Ophthalmopathy Treatment Market Share, By Disease Severity, 2024 & 2033 (%)

Figure 24 North America Graves Ophthalmopathy Treatment Market Share, By End-User, 2024 & 2033 (%)

Figure 25 North America Graves Ophthalmopathy Treatment Market Share, By Country, 2024 & 2033 (%)

Figure 26 Europe Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US$ Billion)

Figure 27 Europe Graves Ophthalmopathy Treatment Market Share, By Medication, 2024 & 2033 (%)

Figure 28 Europe Graves Ophthalmopathy Treatment Market Share, By Disease Severity, 2024 & 2033 (%)

Figure 29 Europe Graves Ophthalmopathy Treatment Market Share, By End-User, 2024 & 2033 (%)

Figure 30 Europe Graves Ophthalmopathy Treatment Market Share, By Country, 2024 & 2033 (%)

Figure 31 Asia-Pacific Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US$ Billion)

Figure 32 Asia-Pacific Graves Ophthalmopathy Treatment Market Share, By Medication, 2024 & 2033 (%)

Figure 33 Asia-Pacific Graves Ophthalmopathy Treatment Market Share, By Disease Severity, 2024 & 2033 (%)

Figure 34 Asia-Pacific Graves Ophthalmopathy Treatment Market Share, By End-User, 2024 & 2033 (%)

Figure 35 Asia-Pacific Graves Ophthalmopathy Treatment Market Share, By Country, 2024 & 2033 (%)

Figure 36 South America Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US$ Billion)

Figure 37 South America Graves Ophthalmopathy Treatment Market Share, By Medication, 2024 & 2033 (%)

Figure 38 South America Graves Ophthalmopathy Treatment Market Share, By Disease Severity, 2024 & 2033 (%)

Figure 39 South America Graves Ophthalmopathy Treatment Market Share, By End-User, 2024 & 2033 (%)

Figure 40 South America Graves Ophthalmopathy Treatment Market Share, By Country, 2024 & 2033 (%)

Figure 41 Middle East and Africa Graves Ophthalmopathy Treatment Market Value, 2022-2033 (US$ Billion)

Figure 42 Middle East and Africa Graves Ophthalmopathy Treatment Market Share, By Medication, 2024 & 2033 (%)

Figure 43 Middle East and Africa Graves Ophthalmopathy Treatment Market Share, By Disease Severity, 2024 & 2033 (%)

Figure 44 Middle East and Africa Graves Ophthalmopathy Treatment Market Share, By End-User, 2024 & 2033 (%)

Figure 45 Amgen Inc.: Financials

Figure 46 Immunovant, Inc.: Financials

Figure 47 Viridian Therapeutics, Inc.: Financials

Figure 48 argenx: Financials

Figure 49 Tourmaline Bio, Inc.: Financials

Figure 50 F. Hoffmann-La Roche Ltd: Financials

Figure 51 Sling Therapeutics: Financials

글로벌 그레이브스 안병증 치료 시장 – 2023-2030

Global Graves Ophthalmopathy Treatment Market - 2023-2030